Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 640,924 shares of its common stock at a price to the […]
